Rizzo P, et al. – The goal of this trial was to elucidate the sequential events and cellular and molecular interactions occurring during crescentic lesion onset and evolution in glomerular diseases. The yielded results supported the possibility that angiotensin–converting enzyme inhibitor treatment could limit parietal epithelial cells (PECs) activation. It could also reduce the frequency and extension of crescents in extracapillary glomerulonephritis (GN).